Description
Owing to its multiple differentiation abilities, the Mesenchymal stromal cells (MSCs) holds the promise in tissue engineering and regenerative medicine, and displays important clinical potential for cell therapy. The Immortalized Human Cord Blood Mesenchymal Stromal Cells with RFP (cbMSC-hTERT-RFP) retains MSC specific surface markers (CD29, CD73, CD105, CD44 and HLA-ABC) as well as its differentiation capacities into cells of the mesodermal lineage, such as osteoblasts and adipocytes. Karyotype analysis and CGH analysis show no chromosomal abnormality nor genomic deletion or amplifications. In addition, transplantation of cbMSC-hTERT-RFP into the rat model with TBI demonstrates that these cells are readily attracted to the injury area and thus provides a valuable cell-based tool forin vivostem cell research and translational study